BI 836826 clinical trials
Also written BI 836826.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How each study uses BI 836826 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BI 836826
- 6
Studies by the year they started
6 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses BI 836826 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic LeukemiaTerminatedPhase 1Gilead SciencesNCT02538614Written as BI 836826
- Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With IbrutinibCompletedPhase 1Boehringer IngelheimNCT02759016Written as BI 836826
- BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)CompletedPhase 1Boehringer IngelheimNCT01296932Written as BI 836826
- BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)CompletedPhase 1Boehringer IngelheimNCT01403948Written as BI 836826
- To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCLCompletedPhase 2Boehringer IngelheimNCT02624492Written as BI 836826
- This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With VenetoclaxWithdrawnPhase 1Boehringer IngelheimNCT03343678Written as BI 836826
Codes
What other systems call BI 836826 · ClinicalTrials.gg INT000914
- MeSH (NLM) C000626798BI 836826One source ClinicalTrials.gov
- UNII (FDA) LB090AB8DBBI-836826One source FDA
- NCI Thesaurus C122833Anti-CD37 Monoclonal Antibody BI 836826One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000626798 | BI 836826 | One source ClinicalTrials.gov |
| UNII (FDA) | LB090AB8DB | BI-836826 | One source FDA |
| NCI Thesaurus | C122833 | Anti-CD37 Monoclonal Antibody BI 836826 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.